The Drug Repurposing Market is becoming an increasingly important part of modern pharmaceutical research and development. Drug repurposing, also known as drug repositioning, involves identifying new therapeutic applications for medicines that have already been developed or investigated for other indications. By leveraging existing knowledge about a drug’s safety, pharmacology, and manufacturing characteristics, companies and researchers can potentially reduce the time and expense associated with developing completely new medicines.
Growing research and development costs, increasing prevalence of chronic diseases, demand for faster therapeutic solutions, and advances in artificial intelligence are supporting the expansion of this market. According to a recent report by Wise Guys Report, the global Drug Repurposing Market was valued at approximately USD 36.7 billion in 2024 and reached USD 38.7 billion in 2025. The market is projected to reach USD 65.0 billion by 2035, expanding at a CAGR of 5.4% during the 2026–2035 forecast period.
Market Drivers
Increasing Drug Development Costs
Traditional drug discovery and development can require extensive investments in laboratory research, clinical studies, regulatory activities, and commercialization. The financial burden associated with discovering and validating new molecules is encouraging pharmaceutical companies to explore alternative development strategies.
Repurposing existing medicines can provide access to previously generated pharmacological and safety information, potentially reducing certain development risks and shortening development timelines. This economic advantage is an important factor supporting market expansion.
Growing Prevalence of Chronic Diseases
The increasing incidence of cancer, neurological disorders, cardiovascular diseases, and other chronic conditions is creating demand for additional therapeutic options. Drug repurposing provides researchers with a mechanism for investigating whether established medicines can address unmet medical needs in different disease areas.
Oncology is particularly important because the continuing global burden of cancer is encouraging researchers to investigate existing drugs for new therapeutic applications. The report identifies oncology as a leading application area and projects this segment to reach approximately USD 26 billion by 2035.
Artificial Intelligence and Machine Learning
AI and machine learning are transforming the identification of potential drug-repurposing candidates. Advanced computational systems can analyze large datasets involving molecular interactions, disease pathways, clinical information, and previously generated research results.
These technologies can help researchers identify relationships that may not be readily apparent through conventional research methods. The growing use of AI is therefore improving candidate screening and supporting faster development strategies.
Demand for Faster Therapeutic Development
Healthcare systems and pharmaceutical companies increasingly seek development approaches that can bring effective treatments to patients more efficiently. Because repurposed medicines may have existing information relating to pharmacology and safety, they can provide an attractive starting point for investigating new indications.
This is particularly valuable when addressing diseases with limited treatment options or urgent public-health requirements.
Growing Focus on Personalized Medicine
The movement toward personalized medicine is encouraging researchers to investigate how existing therapies can be matched to specific patient populations, disease characteristics, or molecular profiles.
Integration of patient data, real-world evidence, computational biology, and clinical information can create additional opportunities for identifying new applications for established medicines.
Market Challenges
Regulatory Complexity
Although repurposed drugs can benefit from existing development information, obtaining regulatory approval for a new indication still requires evidence demonstrating safety, efficacy, and appropriate clinical value.
Regulatory requirements can differ across countries, creating additional complexity for companies seeking to commercialize repurposed therapies internationally.
Limited Intellectual Property Protection
One challenge associated with drug repurposing is intellectual property protection. Existing medicines may have already lost patent protection, potentially reducing commercial incentives for companies to invest heavily in additional clinical development.
Organizations therefore need effective commercialization and intellectual-property strategies to make repurposing programs economically viable.
Clinical Validation Requirements
A drug that is safe or effective for one condition is not automatically effective for another. New therapeutic applications require appropriate preclinical and clinical validation.
Researchers must establish the appropriate dosage, mechanism of action, patient population, safety profile, and clinical benefits for the new indication.
Data Integration Challenges
Drug repurposing increasingly relies on large volumes of biological, clinical, genomic, and real-world data. Integrating information from different databases and ensuring its accuracy can be challenging.
Differences in data quality, accessibility, standards, and privacy requirements can affect the efficiency of computational repurposing programs.
Browse In-depth Market Research Report on Drug Repurposing Market:
Drug Repurposing Market Research Report – WiseGuyReports
Market Segmentation
By Application
- Oncology
- Neurology
- Infectious Diseases
- Cardiology
Oncology represents a particularly significant application segment because of the growing need for new cancer therapies and the large number of existing compounds being investigated for additional indications. Neurology is also gaining attention as researchers explore repurposing opportunities for conditions such as Alzheimer’s and Parkinson’s diseases.
Infectious diseases provide another important area because drug repurposing can potentially support the search for treatment alternatives during emerging health threats. Cardiology continues to offer opportunities due to the substantial burden of cardiovascular diseases worldwide.
By Process
- Preclinical
- Clinical
- Regulatory Approval
- Market Launch
The repurposing process progresses from identifying promising candidates and conducting preclinical investigations to clinical testing, regulatory review, and eventual commercialization.
Preclinical and clinical stages are particularly important for establishing whether an existing drug can safely and effectively be used for its proposed new indication.
By Drug Class
- Small Molecules
- Biologics
- Vaccines
Small-molecule medicines represent an important area for repurposing because many established compounds have extensive historical data. Biologics and vaccines also provide opportunities as advances in biological research reveal new mechanisms and therapeutic applications.
By End User
- Pharmaceutical Companies
- Research Institutions
- Contract Research Organizations
Pharmaceutical companies use repurposing strategies to extend the commercial and therapeutic potential of existing portfolios. Research institutions contribute scientific discoveries and validation studies, while contract research organizations provide specialized preclinical, clinical, analytical, and regulatory support.
By Region
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Regional Insights
North America
North America is expected to maintain its leading position in the global Drug Repurposing Market. The region benefits from advanced healthcare infrastructure, substantial pharmaceutical R&D investment, strong biotechnology capabilities, and growing adoption of AI-driven drug discovery technologies.
The report estimates that the North American market was valued at approximately USD 20 billion in 2024. Strong research capabilities and pharmaceutical-industry partnerships are expected to support continued expansion.
Europe
Europe represents another significant market, supported by established pharmaceutical industries, academic research networks, and regulatory initiatives encouraging innovation.
The region’s focus on collaborative research, digital health, artificial intelligence, and development of treatments for rare and underserved diseases is creating opportunities for drug repurposing programs.
Asia Pacific
Asia Pacific is anticipated to experience strong growth during the forecast period. Increasing healthcare expenditure, expanding pharmaceutical and biotechnology industries, improving research infrastructure, and demand for cost-effective therapies are supporting the regional market.
China, India, Japan, South Korea, and other Asian markets are investing in healthcare innovation and AI technologies, creating a favorable environment for drug-repurposing research.
South America
South America represents an emerging opportunity for drug repurposing as healthcare systems increasingly seek innovative and economically efficient therapeutic approaches.
Growing demand for treatments addressing regional health challenges and improvements in pharmaceutical research capabilities can contribute to future market development.
Middle East and Africa
The Middle East and Africa market is developing gradually as healthcare infrastructure and research capabilities improve. Although limited resources can restrict the pace of adoption in some countries, increasing healthcare investment and interest in innovative treatment strategies may create new opportunities.
Key Players
The competitive landscape includes major pharmaceutical and biotechnology companies involved in drug discovery, development, clinical research, and therapeutic innovation. Key companies identified by WiseGuyReports include Eli Lilly and Company, Takeda Pharmaceutical, AstraZeneca, Biogen, Johnson & Johnson, Amgen, Pfizer, Bristol Myers Squibb, Roche, Merck & Co., AbbVie, Novartis, Sanofi, GlaxoSmithKline, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals.
Companies are pursuing partnerships, AI-enabled discovery platforms, clinical research collaborations, portfolio optimization, and new-indication development to strengthen their positions in the market.
Industry Trends
AI-Enabled Drug Repurposing
Artificial intelligence is becoming a major technology for identifying relationships between existing drugs and potential new disease indications. Machine learning can analyze complex datasets and prioritize candidates for further laboratory and clinical investigation.
Greater Use of Real-World Evidence
Real-world patient information is increasingly being incorporated into repurposing strategies. Clinical records, observational data, and other evidence sources can provide insights into treatment outcomes and potential new therapeutic applications.
Academic-Industry Collaboration
Partnerships between pharmaceutical companies, biotechnology organizations, universities, and research institutions are becoming increasingly important. Such collaborations combine pharmaceutical resources with academic expertise and emerging scientific discoveries.
Focus on Rare and Underserved Diseases
Drug repurposing can be particularly attractive for diseases where conventional commercial incentives for new drug development may be limited. Researchers are therefore investigating existing medicines for rare diseases and conditions with significant unmet medical needs.
Personalized Treatment Strategies
Advances in genomics, molecular medicine, and patient-level data are supporting more targeted repurposing strategies. Researchers can increasingly investigate whether particular medicines may be effective for specific biological or clinical patient subgroups.
Industry Developments
The market is experiencing increased collaboration between pharmaceutical companies and technology-driven drug discovery organizations. Exscientia extended an AI-driven collaboration with Sanofi in March 2024 to investigate repurposing opportunities involving oncology and immune-oncology assets.
In July 2024, Takeda announced a strategic collaboration with Insilico Medicine focused on using AI-based approaches to identify potential new indications within Takeda’s existing portfolio. Roche also entered a multi-year collaboration in January 2025 involving the repurposing of selected oncology agents for new indications.
These developments demonstrate how pharmaceutical companies are increasingly combining established drug portfolios with AI, computational research, and external partnerships to identify new therapeutic opportunities.
Future Outlook
The Drug Repurposing Market is positioned for steady expansion over the coming decade. WiseGuyReports estimates that the market will increase from USD 38.7 billion in 2025 to approximately USD 65.0 billion by 2035, representing a CAGR of 5.4% during 2026–2035.
Future market development will be influenced by rising R&D expenditure, the growing prevalence of chronic diseases, demand for shorter development timelines, regulatory support, and increasing adoption of AI and machine learning. Oncology is expected to remain an important application area, while neurology and infectious diseases could generate additional opportunities.
North America is likely to remain a major center for drug-repurposing research because of its pharmaceutical ecosystem and high R&D investment. Europe should benefit from collaborative research and supportive innovation initiatives, while Asia Pacific is expected to deliver strong growth as healthcare infrastructure, biotechnology capabilities, and investment in pharmaceutical research expand.
Overall, drug repurposing is becoming an increasingly valuable strategy for maximizing the therapeutic potential of existing medicines. The combination of established drug knowledge, advanced data analytics, AI-driven discovery, real-world evidence, and collaborative research could help pharmaceutical and biotechnology companies identify new treatments more efficiently while addressing important unmet medical needs.
